A Deep Dive into Trial Design & Patient Profiles Tags GLP-1 agonists Read more about A Deep Dive into Trial Design & Patient Profiles
Higher-Dose Semaglutide (7.2 mg) Yields Drives Greater Weight and Glycemic Benefits in T2D Read more about Higher-Dose Semaglutide (7.2 mg) Yields Drives Greater Weight and Glycemic Benefits in T2D
Transforming Cardio Metabolic Outcomes with GLP-1 Medicines Tags GLP-1 agonists Read more about Transforming Cardio Metabolic Outcomes with GLP-1 Medicines
SGLT2 Inhibitors Linked to Lower Age-Related Macular Degeneration Risk Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Linked to Lower Age-Related Macular Degeneration Risk
Most Adults on SGLT2 Inhibitors Require Therapy Adjustment Within a Year Tags SGLT-2 Inhibitor Read more about Most Adults on SGLT2 Inhibitors Require Therapy Adjustment Within a Year
Semaglutide Drives Significant Weight Loss in Asian Adults with Obesity Tags SGLT-2 Inhibitor Read more about Semaglutide Drives Significant Weight Loss in Asian Adults with Obesity
OPTION Trial Analysis: Indobufen-Based DAPT Shows Comparable Safety and Efficacy in Diabetes Read more about OPTION Trial Analysis: Indobufen-Based DAPT Shows Comparable Safety and Efficacy in Diabetes
BMJ Launches Living Guidelines on Type 2 Diabetes: Cardio-Renal Risk Now Central to Therapy Decisions Read more about BMJ Launches Living Guidelines on Type 2 Diabetes: Cardio-Renal Risk Now Central to Therapy Decisions
Lilly’s Oral GLP-1 Orforglipron Meets Phase 3 Endpoints in Obesity and Diabetes, Regulatory Filings Planned Read more about Lilly’s Oral GLP-1 Orforglipron Meets Phase 3 Endpoints in Obesity and Diabetes, Regulatory Filings Planned